Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
News Jan 04, 2008
BioFocus DPI will apply Galapagos’ proprietary adenoviral platform to identify drug targets for the development of cancer therapies.
The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in in-vitro assays may provide drug targets for cancer areas with an unmet medical need.
BioFocus DPI receives an upfront payment of €2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to €7.6 million should certain predetermined criteria be achieved.
“This marks BioFocus DPI’s first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Chemists Develop Method to Synthesize Drugs From Renewable PrecursorsNews
Researchers have developed a new approach to the synthesis of benzofurans from cheap raw materials.READ MORE